ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,183.43
0.51%
Dow Jones
38,778.10
0.49%
Gold vs US Dollar
2,313.75
-0.29%
Brent Oil
83.505
-0.47%
Bitcoin
65,660.19
-1.24%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BriaCell Therapeutics Corporation (BCTXW)

  7. BriaCell Therapeutics Corporation (BCTXW) News

BriaCell Therapeutics (BCTXW)

BriaCell Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BCTXW
DateTimeSourceHeadlineSymbolCompany
14/06/202421:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCTXWBriaCell Therapeutics Corporation
14/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCTXWBriaCell Therapeutics Corporation
03/06/202413:00GlobeNewswire Inc.BriaCell Presents Clinical Efficacy Data at ASCO 2024NASDAQ:BCTXWBriaCell Therapeutics Corporation
30/05/202413:00GlobeNewswire Inc.BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast CancerNASDAQ:BCTXWBriaCell Therapeutics Corporation
28/05/202413:00GlobeNewswire Inc.BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human StudyNASDAQ:BCTXWBriaCell Therapeutics Corporation
24/05/202413:58Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BCTXWBriaCell Therapeutics Corporation
24/05/202413:00GlobeNewswire Inc.BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024NASDAQ:BCTXWBriaCell Therapeutics Corporation
20/05/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCTXWBriaCell Therapeutics Corporation
17/05/202421:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCTXWBriaCell Therapeutics Corporation
17/05/202421:33GlobeNewswire Inc.BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingNASDAQ:BCTXWBriaCell Therapeutics Corporation
16/05/202422:10Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BCTXWBriaCell Therapeutics Corporation
15/05/202413:00GlobeNewswire Inc.BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct OfferingNASDAQ:BCTXWBriaCell Therapeutics Corporation
24/04/202413:00GlobeNewswire Inc.BriaCell Announces Oral and Poster Presentations at ASCO 2024NASDAQ:BCTXWBriaCell Therapeutics Corporation
10/04/202413:00GlobeNewswire Inc.BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerNASDAQ:BCTXWBriaCell Therapeutics Corporation
09/04/202413:00GlobeNewswire Inc.BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACRNASDAQ:BCTXWBriaCell Therapeutics Corporation
07/03/202413:00GlobeNewswire Inc.BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ImmunotherapiesNASDAQ:BCTXWBriaCell Therapeutics Corporation
06/03/202413:00GlobeNewswire Inc.BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR ConferenceNASDAQ:BCTXWBriaCell Therapeutics Corporation
27/02/202413:00GlobeNewswire Inc.BriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesNASDAQ:BCTXWBriaCell Therapeutics Corporation
07/02/202413:00GlobeNewswire Inc.BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder CaseNASDAQ:BCTXWBriaCell Therapeutics Corporation
06/02/202413:30GlobeNewswire Inc.Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP ManufacturingNASDAQ:BCTXWBriaCell Therapeutics Corporation
31/01/202403:48GlobeNewswire Inc.BriaCell Therapeutics Corp. Announces Results of Shareholder MeetingNASDAQ:BCTXWBriaCell Therapeutics Corporation
04/01/202413:45GlobeNewswire Inc.BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast CancerNASDAQ:BCTXWBriaCell Therapeutics Corporation
28/12/202313:55GlobeNewswire Inc.BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsNASDAQ:BCTXWBriaCell Therapeutics Corporation
20/12/202313:40GlobeNewswire Inc.BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient SubsetNASDAQ:BCTXWBriaCell Therapeutics Corporation
06/12/202314:31GlobeNewswire Inc.BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSNASDAQ:BCTXWBriaCell Therapeutics Corporation
06/12/202314:00GlobeNewswire Inc.BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical BenefitNASDAQ:BCTXWBriaCell Therapeutics Corporation
30/11/202312:00GlobeNewswire Inc.BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic TumorNASDAQ:BCTXWBriaCell Therapeutics Corporation
03/11/202312:31GlobeNewswire Inc.BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ INDNASDAQ:BCTXWBriaCell Therapeutics Corporation
25/10/202314:15GlobeNewswire Inc.BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology CandidateNASDAQ:BCTXWBriaCell Therapeutics Corporation
20/10/202314:15GlobeNewswire Inc.October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative TechnologyNASDAQ:BCTXWBriaCell Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:BCTXW

Your Recent History

NASDAQ
SSAUX
State Street Target Reti...
LSE
TRAU
Ivz Us Tb Acc
BIT
Q00595
Leonteq Securities
BIT
BDBR
Banco Di Desio E Della B...
EU
HCLAC
Hospices civils de Lyon ...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved